How does nk cells kill cancer

Overview

Natural killer (NK) cells are cytotoxic lymphocytes that play a crucial role in the innate immune system's defense against cancer and viral infections. Discovered in the 1970s by Rolf Kiessling and colleagues at the Karolinska Institute, these cells were named for their ability to spontaneously kill tumor cells without prior sensitization. Unlike adaptive immune cells, NK cells don't require antigen presentation via MHC molecules, allowing them to rapidly respond to cellular abnormalities. They constitute approximately 5-15% of circulating lymphocytes in human peripheral blood and are found in various tissues including the spleen, liver, and bone marrow. NK cell research gained significant momentum in the 1980s with the identification of their surface markers (CD56 and CD16) and the discovery of their 'missing self' hypothesis proposed by Klas Kärre in 1986, explaining how NK cells detect and eliminate cells with reduced MHC class I expression—a common evasion strategy used by cancer cells.

How It Works

NK cells employ multiple mechanisms to kill cancer cells, primarily through direct cytotoxicity and cytokine production. The main killing pathway involves the release of cytotoxic granules containing perforin and granzymes. Perforin creates pores in the target cell membrane, allowing granzymes to enter and activate caspase cascades that induce apoptosis (programmed cell death). NK cells can also express death receptors like Fas ligand and TRAIL that bind to corresponding receptors on cancer cells, triggering extrinsic apoptosis pathways. Additionally, NK cells produce cytokines such as interferon-gamma and tumor necrosis factor-alpha that enhance anti-tumor immune responses by activating macrophages and dendritic cells. NK cell activation is regulated by a balance of activating and inhibitory receptors. Activating receptors like NKG2D recognize stress-induced ligands (such as MICA and MICB) that are upregulated on cancer cells, while inhibitory receptors (like KIRs) detect MHC class I molecules—when cancer cells downregulate MHC class I to evade T-cells, they become vulnerable to NK cell attack through this 'missing self' recognition.

Why It Matters

NK cell-mediated cancer killing is significant because it represents a first-line defense against tumor development and metastasis. Unlike T-cell therapies that require patient-specific customization, NK cells can be used in allogeneic (donor-derived) settings without causing severe graft-versus-host disease, making them promising for off-the-shelf cancer immunotherapies. Clinical applications include adoptive NK cell transfer for hematological malignancies, with studies showing response rates of 30-40% in refractory acute myeloid leukemia. NK cell-based approaches are also being combined with monoclonal antibodies through antibody-dependent cellular cytotoxicity (ADCC), where NK cells recognize antibody-coated cancer cells via their CD16 receptors. Furthermore, NK cells help shape the tumor microenvironment by recruiting other immune cells, making them valuable targets for combination therapies with checkpoint inhibitors and cancer vaccines.